drugset
drugset / Trial / NCT05186051

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS)

NCT05186051 ↗

Phase 2 Completed 3 enrolled Zydus Lifesciences Limited
NaSingle-groupOpen-labelTreatment

Summary

ZYIL1 is expected to show benefit in patients with CAPS. The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects with CAPS.

Timeline

Start
2022-06-01
Primary completion
2022-07-02
Completion
2022-07-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Usnoflast Small molecule 50 mg Oral

Indications

cryopyrin-associated periodic syndrome